Compare Sanofi SA (SNY) vs Ulta Beauty Inc (ULTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Ulta Beauty Inc — how do they compare? Sanofi SA trades at $43.6 (market cap $104.30B), while Ulta Beauty Inc trades at $531.85 (market cap $23.27B). The key difference: Sanofi SA is far larger — about 4.5× Ulta Beauty Inc's market cap, and Sanofi SA pays a 5.55% dividend while Ulta Beauty Inc pays none. Which is the better fit depends on your goals.
| SNY | ULTA | |
|---|---|---|
Market Cap | $104.30B | $23.27B |
Sector | Health | Consumer Cyclical |
52-Week High | $52.34 | $706.82 |
52-Week Low | $41.33 | $450.75 |
Enterprise Value | $124.19B | $25.35B |
Dividend Yield | 5.55% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.62, up 0.32% today, with a neutral technical signal and bullish moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 outlook. Revenue for 2025 was $46.72B with net income of $7.81B, showing improved profitability. Analyst consensus is mixed with 44% Buy, 52% Hold, and 4% Sell ratings. Recent news highlights regulatory approvals for new drugs and pipeline developments under new CEO leadership.
The outlook for SNY is cautiously optimistic, driven by Dupixent's growth and new drug approvals, but faces risks from pipeline setbacks and competition. Earnings momentum and cost discipline support upside potential, though valuation multiples like a P/E of 23.27 may limit near-term gains. Key risks include biosimilar threats post-2031 and ongoing legal challenges. Institutional activity shows increased holdings, reflecting confidence in the company's strategic direction.
ULTA stock trades at $532.14, down 3.01% today, amid mixed technical signals with a bullish moving average trend but neutral oscillators. The company reported Q1 2026 EPS of $7.74, beating expectations, and maintains strong profitability with a 39.33% gross margin and 47.45% ROE. Recent news highlights Ulta's omnichannel growth strategy and the end of its Target partnership, viewed as a potential revenue opportunity by analysts.
Outlook is positive with a consensus price target of $618.29, representing 16% upside, supported by 56.53% analyst buy ratings. Risks include margin compression, with net income margin projected to drop to 9.35% in 2026, and volatile cash flows, as net cash flow turned negative in 2025. Investors should weigh strong fundamentals against competitive and execution risks in the retail sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Ulta Beauty Inc
With more than 1,300 stores and a partnership with Target, Ulta Beauty is the largest specialized beauty retailer in the U.S. The firm offers makeup (43% of 2021 sales), fragrances, skin care, and hair care products (20% of 2021 sales), and bath and body items. Ulta offers private-label products and merchandise from more than 500 vendors. It also offers salon services, including hair, makeup, skin, and brow services, in all stores. Most Ulta stores are approximately 10,000 square feet and are in suburban strip centers. Ulta was founded in 1990 and is based in Bolingbrook, Illinois.
Read more on ULTA →
